Evidence map›Paper›PMID 32232138›Full record

ArticleACS central science2020

Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy.

Xianwu Wang, Shuyao Lang, Yunpeng Tian, Jianghong Zhang, Xu Yan, Zhihong Fang, Jian Weng, Na Lu, Xuanjun Wu, Tianlu Li and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Glycoengineering in antigen-specific immunotherapies.Current opinion in chemical biology · 2024
    Review
  9. Review
  10. Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Xianwu WangDepartment of Biomaterials, College of Materials, Xiamen University, 422 Siming Nan Road, Xiamen 361005, P. R. China.
Shuyao LangDepartments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States.
Yunpeng TianXiamen Nuokangde Biological Technology Co., Ltd., Xiamen 361006, China.
Jianghong ZhangXiamen Nuokangde Biological Technology Co., Ltd., Xiamen 361006, China.
Xu YanSchool of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China.
Zhihong FangDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Jian WengDepartment of Biomaterials, College of Materials, Xiamen University, 422 Siming Nan Road, Xiamen 361005, P. R. China.
Na LuNational Glycoengineering Research Center, Shandong University, Qingdao, Shandong 266237, China.
Xuanjun WuDepartments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States.
Tianlu LiDepartments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States.
Hongzhi CaoNational Glycoengineering Research Center, Shandong University, Qingdao, Shandong 266237, China.
Zhu LiXiamen Nuokangde Biological Technology Co., Ltd., Xiamen 361006, China.
Xuefei HuangDepartments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States.
Shandong University · CNMichigan State University · USXiamen University · CNFirst Affiliated Hospital of Xiamen University · CNSun Yat-sen University · CN

Funding

Generation of active immunity against cytotoxic oligomeric tau speciesR01CA225105 · NCI · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2018 to 2023
$2.8M
NCI NIH HHS R01 CA225105
6 · The paper itself

Abstract

Adoptive transfer of immune cells is being actively pursued for cancer treatment. Natural killer (NK) cells, a class of cytotoxic immune cells, generally lack inherent selectivities toward cancer. To bestow tumor-targeting abilities and enhance anticancer efficacy, a new strategy is established to glycoengineer NK cells. Carbohydrate-based ligands for CD22, a marker for B cell lymphoma, are introduced onto NK cells through either metabolic engineering or glyco-polymer insertion. Such NK cells exhibited greatly enhanced cytotoxicities toward CD22

Identifiers

PMID32232138
PMCPMC7099595
OpenAlexW3009667530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.